SlideShare a Scribd company logo
1 of 11
REVISED McDONALD’S CRITERIA
2017
DR SUDHIR KUMAR MD DM
CONSULTANT NEUROLOGIST
APOLLO HOSPITALS, HYDERABAD
Position Paper
Rationale and methods for the 2017 revisions
 Performance of the 2010 McDonald criteria in diverse
populations
 The distinction between multiple sclerosis and other
diseases with potentially overlapping clinical and imaging
features, such as neuromyelitis optica spectrum disorders
(NMOSDs)
 Challenges in making the diagnosis in individuals with
presentations other than a typical clinically isolated
syndrome
 The frequency and consequences of misdiagnosis
 CSF and other paraclinical tests that could be used to
diagnose multiple sclerosis
3
2010 vs 2017 McDonald`s Criteria Attack Onset
Clinical Attacks Additional Data Needed
≥2 attacks
Objective evidence of
≥2 lesions or
objective
clinical evidence of 1
lesion with
reasonable historical
evidence
 None. Clinical evidence is sufficient.
≥2 attacks
Objective clinical
evidence of 1 lesion
For dissemination in space (DIS),
demonstrated by
 ≥1 T2 lesion in at least 2 of 4 MS-typical
regions of the CNS*; or await a further
clinical attack implicating
a different CNS site
1 attack
Objective clinical
evidence of ≥2
lesions
For dissemination in time (DIT),
demonstrated by
 Simultaneous presence of asymptomatic
Gd+ and nonenhancing lesions; or a new
T2 and/or Gd+ lesion on follow-up MRI,
irrespective of timing with reference to a
baseline scan; or await a second clinical
attack
1 attack
Objective clinical
evidence of 1 lesion
(CIS)
 For DIS: ≥1 T2 lesion in at least 2 of 4 MS-
typical regions of the CNS*; or await a
further clinical attack implicating a
different CNS site
 For DIT: Simultaneous presence of
asymptomatic Gd+ and nonenhancing
lesions; or a new T2 and/or
Gd+ lesion on follow-up MRI, irrespective
of timing with reference to a baseline
scan; or await a second clinical attack Polman CH et al. Ann Neurol. 2011;69:292-302
McDonald`s 2010 Attack onset
Clinical Attacks Additional Data
Needed
≥2 Clinical attacks and
objective clinical evidence of
≥2 lesions
None
≥2 clinical attacks and
objective evidence of 1 lesion
DIS- an additional clinical
attack
implicating a different CNS
site or by MRI
1 Clinical attack and objective
clinical evidence ≥2 lesions
DIT- an additional clinical
attack OR by MRI OR
demonstration of CSF-specific
oligoclonal bands
1 clinical attack and objective
clinical evidence of 1 lesion
DIS -an additional clinical
attack
implicating a different CNS
site or by MR
AND
DIT - an additional clinical
attack or by
MRI OR demonstration of
CSF-specific oligoclonal bands
McDonald`s 2017 Attack onset
MAGNIMS vs McDonald`s 2017 ( DIS Criteria)
5
MAGNIMS 2017 McDonald`s 2017
Lancet Neurol 2016; 15: 292–303
• MAGNIMS recommended Three Periventricular Lesions and optic
nerve lesion which is not included in McDonald 2017
2010 vs 2017 McDonald`s DIS Criteria
McDonald`s 2017 DIT Criteria
McDonald`s 2017 DIT Criteria
DIT can be demonstrated by
• Simultaneous presence of gadolinium-enhancing and
non-enhancing lesions at any time, OR
• A new T2W hyperintense or gadolinium-enhancing lesion
on the follow up MRI with reference to the baseline scan,
irrespective of the timing of baseline MRI.
(Change from 2010: No difference between symptomatic and asymptomatic
lesions)
HIGHLIGHTS
CSF-specific OCBs are back (were part of Poser criteria)
– and allow an MS diagnosis in certain situations
Symptomatic and asymptomatic MRI lesions can be
considered in the determination of DIS or DIT
Cortical and juxtacortical lesions can be used in
fulfilling MRI criteria for DIS
A provisional disease course should be provided and
periodically reassessed according to Lublin 2014 MS
phenotypes
PPMS No changes beyond the removal of the
distinction between symptomatic and asymptomatic
lesions and that cortical lesions can be used
Impact on India
• Optic lesions are not included
• OCB testing is not yet standardized in India
• Differentiation between Juxtacortical and Cortical will
be a challenge because of Low Tesla MRI
10
Comments/Discussion?

More Related Content

What's hot

Neurosarcoidosis
NeurosarcoidosisNeurosarcoidosis
NeurosarcoidosisAde Wijaya
 
Guillain Barre syndrome
Guillain Barre syndromeGuillain Barre syndrome
Guillain Barre syndromeSiva Pesala
 
Neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorderNeuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorderNeurologyKota
 
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Ade Wijaya
 
Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome (LEMS)Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome (LEMS)Chee Oh
 
Myathenia Gravis
Myathenia GravisMyathenia Gravis
Myathenia GravisAmr Hassan
 
Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disordersNeuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disordersNeurologyKota
 
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndromePosterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndromePrashant Makhija
 
Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension Ade Wijaya
 
Metabolic encephalopathies 2
Metabolic encephalopathies 2Metabolic encephalopathies 2
Metabolic encephalopathies 2Riham Nasar
 
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD]
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD] Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD]
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD] Ade Wijaya
 
Advances in myasthenia gravis
Advances in myasthenia gravisAdvances in myasthenia gravis
Advances in myasthenia gravisNeurologyKota
 
Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy Ajay Kumar
 
Vasculitic neuropathies.pptx
Vasculitic neuropathies.pptxVasculitic neuropathies.pptx
Vasculitic neuropathies.pptxNeurologyKota
 
Approach to demyelinating diseases
Approach to demyelinating diseasesApproach to demyelinating diseases
Approach to demyelinating diseasesNeurologyKota
 
Small Vessel Disease
Small Vessel DiseaseSmall Vessel Disease
Small Vessel DiseaseAhmed Mohamed
 
Approach to hemiplegia
Approach to hemiplegiaApproach to hemiplegia
Approach to hemiplegiaSudhir Kumar
 

What's hot (20)

Neurosarcoidosis
NeurosarcoidosisNeurosarcoidosis
Neurosarcoidosis
 
Epilepsy surgery
Epilepsy surgeryEpilepsy surgery
Epilepsy surgery
 
Guillain Barre syndrome
Guillain Barre syndromeGuillain Barre syndrome
Guillain Barre syndrome
 
Neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorderNeuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder
 
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage
 
Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome (LEMS)Lambert Eaton Myasthenic Syndrome (LEMS)
Lambert Eaton Myasthenic Syndrome (LEMS)
 
Myathenia Gravis
Myathenia GravisMyathenia Gravis
Myathenia Gravis
 
Neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disordersNeuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders
 
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndromePosterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome
 
Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension Idiopathic Intracranial Hypertension
Idiopathic Intracranial Hypertension
 
Metabolic encephalopathies 2
Metabolic encephalopathies 2Metabolic encephalopathies 2
Metabolic encephalopathies 2
 
Cidp ajay
Cidp ajayCidp ajay
Cidp ajay
 
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD]
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD] Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD]
Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease [MOG-AD]
 
Advances in myasthenia gravis
Advances in myasthenia gravisAdvances in myasthenia gravis
Advances in myasthenia gravis
 
Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy Chronic inflammatory demyelinating Polyradiculoneuropathy
Chronic inflammatory demyelinating Polyradiculoneuropathy
 
Vasculitic neuropathies.pptx
Vasculitic neuropathies.pptxVasculitic neuropathies.pptx
Vasculitic neuropathies.pptx
 
Approach to demyelinating diseases
Approach to demyelinating diseasesApproach to demyelinating diseases
Approach to demyelinating diseases
 
Small Vessel Disease
Small Vessel DiseaseSmall Vessel Disease
Small Vessel Disease
 
Dystonia
DystoniaDystonia
Dystonia
 
Approach to hemiplegia
Approach to hemiplegiaApproach to hemiplegia
Approach to hemiplegia
 

Similar to Multiple sclerosis: Revised diagnostic criteria

Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illness
Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illnessNeuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illness
Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illnessdrsandhyamanorenj2
 
MS for clerks.ppt
MS for clerks.pptMS for clerks.ppt
MS for clerks.pptHsuMidori
 
multiple sclerosis- recent guidelines 2018
multiple sclerosis- recent guidelines 2018multiple sclerosis- recent guidelines 2018
multiple sclerosis- recent guidelines 2018NeurologyKota
 
Differential diagnosis of suspected multiple sclerosis
Differential diagnosis of suspected multiple sclerosisDifferential diagnosis of suspected multiple sclerosis
Differential diagnosis of suspected multiple sclerosisNeurology resident slides
 
Neuroinflammatory_disorders_MS_Alhareb.pptx
Neuroinflammatory_disorders_MS_Alhareb.pptxNeuroinflammatory_disorders_MS_Alhareb.pptx
Neuroinflammatory_disorders_MS_Alhareb.pptxAhmedalmahdi16
 
Prediction of outcome of Multiple sclerosis
Prediction of outcome of Multiple sclerosisPrediction of outcome of Multiple sclerosis
Prediction of outcome of Multiple sclerosisAmr Hassan
 
Monitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientMonitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientPramod Krishnan
 
Has AMD management changed these days-DR AJAY DUANI
Has AMD management changed these days-DR AJAY DUANIHas AMD management changed these days-DR AJAY DUANI
Has AMD management changed these days-DR AJAY DUANIAjayDudani1
 
Tactics and techniques in management of Multiple sclerosis
Tactics and techniques in management of Multiple sclerosisTactics and techniques in management of Multiple sclerosis
Tactics and techniques in management of Multiple sclerosisAmr Hassan
 
Neuroimaging Mastery Project: Presentation #5 Subdural Hematomas
Neuroimaging Mastery Project: Presentation #5 Subdural HematomasNeuroimaging Mastery Project: Presentation #5 Subdural Hematomas
Neuroimaging Mastery Project: Presentation #5 Subdural HematomasSean M. Fox
 
ANVS (NYSE American) Annovis Presentation - January 2021
ANVS (NYSE American) Annovis Presentation -  January 2021ANVS (NYSE American) Annovis Presentation -  January 2021
ANVS (NYSE American) Annovis Presentation - January 2021RedChip Companies, Inc.
 
Ueda2016 diabetic retinopathy - sehnaz karadeniz
Ueda2016 diabetic retinopathy - sehnaz karadenizUeda2016 diabetic retinopathy - sehnaz karadeniz
Ueda2016 diabetic retinopathy - sehnaz karadenizueda2015
 
2022-10-12 The future of population health_Alain van Gool.pdf
2022-10-12 The future of population health_Alain van Gool.pdf2022-10-12 The future of population health_Alain van Gool.pdf
2022-10-12 The future of population health_Alain van Gool.pdfAlain van Gool
 
Screening lecture for sims Lahore and Post Graduatestudents 2017
Screening lecture for sims Lahore  and Post Graduatestudents 2017Screening lecture for sims Lahore  and Post Graduatestudents 2017
Screening lecture for sims Lahore and Post Graduatestudents 2017Tauseef Jawaid
 

Similar to Multiple sclerosis: Revised diagnostic criteria (20)

Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illness
Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illnessNeuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illness
Neuromyelitis optica spectrum disorder -NMOSD : An AQP4 antibody illness
 
MS for clerks.ppt
MS for clerks.pptMS for clerks.ppt
MS for clerks.ppt
 
multiple sclerosis- recent guidelines 2018
multiple sclerosis- recent guidelines 2018multiple sclerosis- recent guidelines 2018
multiple sclerosis- recent guidelines 2018
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
Multiple sclerosis
Multiple sclerosisMultiple sclerosis
Multiple sclerosis
 
What's New in Multiple Sclerosis
What's New in Multiple SclerosisWhat's New in Multiple Sclerosis
What's New in Multiple Sclerosis
 
Differential diagnosis of suspected multiple sclerosis
Differential diagnosis of suspected multiple sclerosisDifferential diagnosis of suspected multiple sclerosis
Differential diagnosis of suspected multiple sclerosis
 
Neuroinflammatory_disorders_MS_Alhareb.pptx
Neuroinflammatory_disorders_MS_Alhareb.pptxNeuroinflammatory_disorders_MS_Alhareb.pptx
Neuroinflammatory_disorders_MS_Alhareb.pptx
 
Prediction of outcome of Multiple sclerosis
Prediction of outcome of Multiple sclerosisPrediction of outcome of Multiple sclerosis
Prediction of outcome of Multiple sclerosis
 
Monitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patientMonitoring the Multiple Sclerosis patient
Monitoring the Multiple Sclerosis patient
 
Has AMD management changed these days-DR AJAY DUANI
Has AMD management changed these days-DR AJAY DUANIHas AMD management changed these days-DR AJAY DUANI
Has AMD management changed these days-DR AJAY DUANI
 
Tactics and techniques in management of Multiple sclerosis
Tactics and techniques in management of Multiple sclerosisTactics and techniques in management of Multiple sclerosis
Tactics and techniques in management of Multiple sclerosis
 
Magnims
MagnimsMagnims
Magnims
 
Scientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple SclerosisScientifi c Journal of Multiple Sclerosis
Scientifi c Journal of Multiple Sclerosis
 
Neuroimaging Mastery Project: Presentation #5 Subdural Hematomas
Neuroimaging Mastery Project: Presentation #5 Subdural HematomasNeuroimaging Mastery Project: Presentation #5 Subdural Hematomas
Neuroimaging Mastery Project: Presentation #5 Subdural Hematomas
 
Annovis Presentation - February 2021
Annovis Presentation - February 2021Annovis Presentation - February 2021
Annovis Presentation - February 2021
 
ANVS (NYSE American) Annovis Presentation - January 2021
ANVS (NYSE American) Annovis Presentation -  January 2021ANVS (NYSE American) Annovis Presentation -  January 2021
ANVS (NYSE American) Annovis Presentation - January 2021
 
Ueda2016 diabetic retinopathy - sehnaz karadeniz
Ueda2016 diabetic retinopathy - sehnaz karadenizUeda2016 diabetic retinopathy - sehnaz karadeniz
Ueda2016 diabetic retinopathy - sehnaz karadeniz
 
2022-10-12 The future of population health_Alain van Gool.pdf
2022-10-12 The future of population health_Alain van Gool.pdf2022-10-12 The future of population health_Alain van Gool.pdf
2022-10-12 The future of population health_Alain van Gool.pdf
 
Screening lecture for sims Lahore and Post Graduatestudents 2017
Screening lecture for sims Lahore  and Post Graduatestudents 2017Screening lecture for sims Lahore  and Post Graduatestudents 2017
Screening lecture for sims Lahore and Post Graduatestudents 2017
 

More from Sudhir Kumar

Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
Lifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptxLifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptxSudhir Kumar
 
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatment
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatmentCOVID-19 Presenting as stroke- mechanisms, diagnosis and treatment
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatmentSudhir Kumar
 
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?Sudhir Kumar
 
Neurological Manifestations of COVID-19 Infection
Neurological Manifestations of COVID-19 InfectionNeurological Manifestations of COVID-19 Infection
Neurological Manifestations of COVID-19 InfectionSudhir Kumar
 
ZONISAMIDE IN TREATMENT OF EPILEPSY
ZONISAMIDE IN TREATMENT OF EPILEPSYZONISAMIDE IN TREATMENT OF EPILEPSY
ZONISAMIDE IN TREATMENT OF EPILEPSYSudhir Kumar
 
Multiple sclerosis: fighting the invisible
Multiple sclerosis: fighting the  invisibleMultiple sclerosis: fighting the  invisible
Multiple sclerosis: fighting the invisibleSudhir Kumar
 
Managing stroke beyond windlow period
Managing stroke beyond windlow periodManaging stroke beyond windlow period
Managing stroke beyond windlow periodSudhir Kumar
 
WHEN STROKE STRIKES PREGNANCY
WHEN STROKE STRIKES PREGNANCYWHEN STROKE STRIKES PREGNANCY
WHEN STROKE STRIKES PREGNANCYSudhir Kumar
 
MANAGEMENT OF ACUTE STROKE
MANAGEMENT OF ACUTE STROKEMANAGEMENT OF ACUTE STROKE
MANAGEMENT OF ACUTE STROKESudhir Kumar
 
NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosisSudhir Kumar
 
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTS
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTSNEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTS
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTSSudhir Kumar
 
Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Sudhir Kumar
 
Marketing one's Products and Skills
Marketing one's Products and SkillsMarketing one's Products and Skills
Marketing one's Products and SkillsSudhir Kumar
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)Sudhir Kumar
 
Role of Blood Pressure in Recurrent Stroke
Role of Blood Pressure in Recurrent StrokeRole of Blood Pressure in Recurrent Stroke
Role of Blood Pressure in Recurrent StrokeSudhir Kumar
 
Palmitoylethanolamide in the Treatment of Neuropathic Pain
Palmitoylethanolamide in the Treatment of Neuropathic Pain Palmitoylethanolamide in the Treatment of Neuropathic Pain
Palmitoylethanolamide in the Treatment of Neuropathic Pain Sudhir Kumar
 
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseNewer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseSudhir Kumar
 
Management of acute stroke
Management of acute strokeManagement of acute stroke
Management of acute strokeSudhir Kumar
 

More from Sudhir Kumar (20)

Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
Lifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptxLifestyle Measures to Prevent Brain Diseases.pptx
Lifestyle Measures to Prevent Brain Diseases.pptx
 
MIGRAINE
MIGRAINEMIGRAINE
MIGRAINE
 
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatment
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatmentCOVID-19 Presenting as stroke- mechanisms, diagnosis and treatment
COVID-19 Presenting as stroke- mechanisms, diagnosis and treatment
 
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
CHRONIC PAIN AND DEPRESSION: Cause or Effect or Linked?
 
Neurological Manifestations of COVID-19 Infection
Neurological Manifestations of COVID-19 InfectionNeurological Manifestations of COVID-19 Infection
Neurological Manifestations of COVID-19 Infection
 
ZONISAMIDE IN TREATMENT OF EPILEPSY
ZONISAMIDE IN TREATMENT OF EPILEPSYZONISAMIDE IN TREATMENT OF EPILEPSY
ZONISAMIDE IN TREATMENT OF EPILEPSY
 
Multiple sclerosis: fighting the invisible
Multiple sclerosis: fighting the  invisibleMultiple sclerosis: fighting the  invisible
Multiple sclerosis: fighting the invisible
 
Managing stroke beyond windlow period
Managing stroke beyond windlow periodManaging stroke beyond windlow period
Managing stroke beyond windlow period
 
WHEN STROKE STRIKES PREGNANCY
WHEN STROKE STRIKES PREGNANCYWHEN STROKE STRIKES PREGNANCY
WHEN STROKE STRIKES PREGNANCY
 
MANAGEMENT OF ACUTE STROKE
MANAGEMENT OF ACUTE STROKEMANAGEMENT OF ACUTE STROKE
MANAGEMENT OF ACUTE STROKE
 
NEDA in multiple sclerosis
NEDA in multiple sclerosisNEDA in multiple sclerosis
NEDA in multiple sclerosis
 
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTS
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTSNEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTS
NEUROLOGICAL DISORDERS DUE TO METABOLIC DERANGEMENTS
 
Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)Management of High Disease Activity in Multiple Sclerosis (MS)
Management of High Disease Activity in Multiple Sclerosis (MS)
 
Marketing one's Products and Skills
Marketing one's Products and SkillsMarketing one's Products and Skills
Marketing one's Products and Skills
 
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)Addressing hypertension to reduce  the burden of stroke 19 feb2018 (1)
Addressing hypertension to reduce the burden of stroke 19 feb2018 (1)
 
Role of Blood Pressure in Recurrent Stroke
Role of Blood Pressure in Recurrent StrokeRole of Blood Pressure in Recurrent Stroke
Role of Blood Pressure in Recurrent Stroke
 
Palmitoylethanolamide in the Treatment of Neuropathic Pain
Palmitoylethanolamide in the Treatment of Neuropathic Pain Palmitoylethanolamide in the Treatment of Neuropathic Pain
Palmitoylethanolamide in the Treatment of Neuropathic Pain
 
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's DiseaseNewer drugs for the treatment of motor symptoms of Parkinson's Disease
Newer drugs for the treatment of motor symptoms of Parkinson's Disease
 
Management of acute stroke
Management of acute strokeManagement of acute stroke
Management of acute stroke
 

Recently uploaded

Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...DrShinyKajal
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialSherrylee83
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATROKanhu Charan
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024locantocallgirl01
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxDr. Rabia Inam Gandapore
 
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...TEST BANK For Nursing Leadership, Management, and Professional Practice for t...
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...rightmanforbloodline
 
Histopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesHistopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesPHARMA IQ EDUCATION
 
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdfUnveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdfNoorulainMehmood1
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsMedicoseAcademics
 
Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?bkling
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUELMKARTHIKEMMANUEL
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalGokuldas Hospital
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptxclaviclebrown44
 
BURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdfBURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdfDolisha Warbi
 
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upsupply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upSherrylee83
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Health Kinesiology Natural Bioenergetics
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answersShafnaP5
 
Buy 5cladba from 5cl precursor supplier with strong effect
Buy 5cladba from 5cl precursor supplier with strong effectBuy 5cladba from 5cl precursor supplier with strong effect
Buy 5cladba from 5cl precursor supplier with strong effectSherrylee83
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...JRRolfNeuqelet
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxMohammadAbuzar19
 

Recently uploaded (20)

Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...Storage of Blood Components- equipments, effects of improper storage, transpo...
Storage of Blood Components- equipments, effects of improper storage, transpo...
 
How to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw materialHow to buy 5cladba precursor raw 5cl-adb-a raw material
How to buy 5cladba precursor raw 5cl-adb-a raw material
 
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATROROSE  CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
ROSE CASE SPINAL SBRT BY DR KANHU CHARAN PATRO
 
Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024Top 10 Most Beautiful Russian Pornstars List 2024
Top 10 Most Beautiful Russian Pornstars List 2024
 
Face and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptxFace and Muscles of facial expression.pptx
Face and Muscles of facial expression.pptx
 
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...TEST BANK For Nursing Leadership, Management, and Professional Practice for t...
TEST BANK For Nursing Leadership, Management, and Professional Practice for t...
 
Histopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseasesHistopathological staining techniques used in liver diseases
Histopathological staining techniques used in liver diseases
 
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdfUnveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
Unveiling Pharyngitis: Causes, Symptoms, Diagnosis, and Treatment Strategies.pdf
 
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose AcademicsHistology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
Histology of Epithelium - Dr Muhammad Ali Rabbani - Medicose Academics
 
Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?Report Back from SGO: What’s the Latest in Ovarian Cancer?
Report Back from SGO: What’s the Latest in Ovarian Cancer?
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Treatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas HospitalTreatment Choices for Slip Disc at Gokuldas Hospital
Treatment Choices for Slip Disc at Gokuldas Hospital
 
Failure to thrive in neonates and infants + pediatric case.pptx
Failure to thrive in neonates and infants  + pediatric case.pptxFailure to thrive in neonates and infants  + pediatric case.pptx
Failure to thrive in neonates and infants + pediatric case.pptx
 
BURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdfBURNS (CLASSIFICATION & MANAGEMENTS).pdf
BURNS (CLASSIFICATION & MANAGEMENTS).pdf
 
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-upsupply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
supply cas 5449-12-7 BMK glycidic acid(powder) in stock EU pick-up
 
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
Unlocking Holistic Wellness: Addressing Depression, Mental Well-Being, and St...
 
Mgr university bsc nursing adult health previous question paper with answers
Mgr university  bsc nursing adult health previous question paper with answersMgr university  bsc nursing adult health previous question paper with answers
Mgr university bsc nursing adult health previous question paper with answers
 
Buy 5cladba from 5cl precursor supplier with strong effect
Buy 5cladba from 5cl precursor supplier with strong effectBuy 5cladba from 5cl precursor supplier with strong effect
Buy 5cladba from 5cl precursor supplier with strong effect
 
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
VIII.1 Nursing Interventions to Promote Healthy Psychological responses, SELF...
 
Drug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptxDrug development life cycle indepth overview.pptx
Drug development life cycle indepth overview.pptx
 

Multiple sclerosis: Revised diagnostic criteria

  • 1. REVISED McDONALD’S CRITERIA 2017 DR SUDHIR KUMAR MD DM CONSULTANT NEUROLOGIST APOLLO HOSPITALS, HYDERABAD
  • 3. Rationale and methods for the 2017 revisions  Performance of the 2010 McDonald criteria in diverse populations  The distinction between multiple sclerosis and other diseases with potentially overlapping clinical and imaging features, such as neuromyelitis optica spectrum disorders (NMOSDs)  Challenges in making the diagnosis in individuals with presentations other than a typical clinically isolated syndrome  The frequency and consequences of misdiagnosis  CSF and other paraclinical tests that could be used to diagnose multiple sclerosis 3
  • 4. 2010 vs 2017 McDonald`s Criteria Attack Onset Clinical Attacks Additional Data Needed ≥2 attacks Objective evidence of ≥2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence  None. Clinical evidence is sufficient. ≥2 attacks Objective clinical evidence of 1 lesion For dissemination in space (DIS), demonstrated by  ≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS*; or await a further clinical attack implicating a different CNS site 1 attack Objective clinical evidence of ≥2 lesions For dissemination in time (DIT), demonstrated by  Simultaneous presence of asymptomatic Gd+ and nonenhancing lesions; or a new T2 and/or Gd+ lesion on follow-up MRI, irrespective of timing with reference to a baseline scan; or await a second clinical attack 1 attack Objective clinical evidence of 1 lesion (CIS)  For DIS: ≥1 T2 lesion in at least 2 of 4 MS- typical regions of the CNS*; or await a further clinical attack implicating a different CNS site  For DIT: Simultaneous presence of asymptomatic Gd+ and nonenhancing lesions; or a new T2 and/or Gd+ lesion on follow-up MRI, irrespective of timing with reference to a baseline scan; or await a second clinical attack Polman CH et al. Ann Neurol. 2011;69:292-302 McDonald`s 2010 Attack onset Clinical Attacks Additional Data Needed ≥2 Clinical attacks and objective clinical evidence of ≥2 lesions None ≥2 clinical attacks and objective evidence of 1 lesion DIS- an additional clinical attack implicating a different CNS site or by MRI 1 Clinical attack and objective clinical evidence ≥2 lesions DIT- an additional clinical attack OR by MRI OR demonstration of CSF-specific oligoclonal bands 1 clinical attack and objective clinical evidence of 1 lesion DIS -an additional clinical attack implicating a different CNS site or by MR AND DIT - an additional clinical attack or by MRI OR demonstration of CSF-specific oligoclonal bands McDonald`s 2017 Attack onset
  • 5. MAGNIMS vs McDonald`s 2017 ( DIS Criteria) 5 MAGNIMS 2017 McDonald`s 2017 Lancet Neurol 2016; 15: 292–303 • MAGNIMS recommended Three Periventricular Lesions and optic nerve lesion which is not included in McDonald 2017
  • 6. 2010 vs 2017 McDonald`s DIS Criteria
  • 8. McDonald`s 2017 DIT Criteria DIT can be demonstrated by • Simultaneous presence of gadolinium-enhancing and non-enhancing lesions at any time, OR • A new T2W hyperintense or gadolinium-enhancing lesion on the follow up MRI with reference to the baseline scan, irrespective of the timing of baseline MRI. (Change from 2010: No difference between symptomatic and asymptomatic lesions)
  • 9. HIGHLIGHTS CSF-specific OCBs are back (were part of Poser criteria) – and allow an MS diagnosis in certain situations Symptomatic and asymptomatic MRI lesions can be considered in the determination of DIS or DIT Cortical and juxtacortical lesions can be used in fulfilling MRI criteria for DIS A provisional disease course should be provided and periodically reassessed according to Lublin 2014 MS phenotypes PPMS No changes beyond the removal of the distinction between symptomatic and asymptomatic lesions and that cortical lesions can be used
  • 10. Impact on India • Optic lesions are not included • OCB testing is not yet standardized in India • Differentiation between Juxtacortical and Cortical will be a challenge because of Low Tesla MRI 10